RNU6-559P

Across TCGA pan-cancer cohorts, RNU6-559P RNA is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated RNU6-559P data layer.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RNU6-559P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-559P expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

OV, STAD, and LIHC are the cancer types where RNU6-559P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Tertile	II,III,IV	0.300	0.691	.027	54	view →
STAD	DFS	Tertile	II,III,IV	0.292	0.544	.019	45	view →
LIHC	DFS	Tertile	All	0.093	0.543	.019	18	view →
LAML	DFS	Tertile	All	0.167	0.589	.005	18	view →
ESCA	OS	Tertile	III,IV	1.000	0.374	.043	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RNU6-559P–OV (OS)

Open the OV breakdown →